Novel nucleosides, their preparation and pharmaceutical compositions

Abstract: Novel bis-dideoxynucleosides are useful in the treatment of retroviral infections, particularly HIV infections.

Description: The instant invention comprises compounds which exhibit antiretroviral activity. These compounds act to interfere with the viral life cycle, but do not exhibit the extreme toxic effects on the normal cellular processes of mammalian host cells. The instant invention also comprises the synthesis of the compounds of the invention. The instant invention also comprises pharmaceutical preparations which are useful for preventing a retroviral infection in a subject or treating a subject infected with a retrovirus, particularly preventing an HIV infection in a subject or treating a subject infected with the HIV virus. The use of 2',3'-dideoxynucleosides in the treatment of viral infections is known from EP-A-0 206 497. EP-A-0 199 451 discloses 3'-azido-2',3'-dideoxythymidines and their use in the treatment of bacterial or viral infections. The compounds of the instant invention are represented by the general formula A- B- C I wherein A and C are each independently dideoxynucleoside radicals: and B is a linking group represented by the formula a) -C(X)-(CH₂) n -C(X)- b) -C(X)- c) -C(X)-NH-S(O)(O)- d) -C(O)-CH₂-S(O)(O)- e) -P(O)CH₃- f) -C(O)O-(CH₂)₂-S(O)(O)-(CH₂)₂-OC(O)- g) -C(O)-(CH₂)₂-S-S-(CH₂)₂-C(O)- h) -C(O)-(CH₂)₂-C(O)O-(CH₂)₂-OC(O)-(CH₂)-C(O)- wherein X is O or S; n is 2-6; B is attached to A at either the 5' hydroxy group or an amino group of A: and C is attached to B at either the 5' hydroxy group or an amino group of C; or the pharmaceutically acceptable salts. The term dideoxynucleoside radical means any 2',3'dideoxy analog of adenosine, thymidine, cytidine, guanosine, uridine or inosine having a free valence bond. Particularly included are substituted 2',3' dideoxynucleoside radicals of the above general formula where the substituents are those such as amino, halogen, alkyl, azido, and cyano. Preferred moieties A and C are moieties of dideoxycytidine, dideoxy adenosine and 3'-azido-3'-deoxythymidine. Compounds wherein A is a moiety of dideoxycytidine are especially preferred. Examples of preferred compounds are 3'-Azido-3'-deoxy -4[[1-[2',3'-dideoxy-pentofuranosyl)-1,2-dihydro-2-oxo-pyrimidinyl]amino]-beta-D-erythro-thymidine 5'-(4-oxo-butanoate) (ester), N,N'-(1,5-dioxo-1,5-pentanediyl)bis(2',3'-dideoxycytidine), 2',3'-Dideoxy-5-[[1-(2',3'-dideoxypentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]cytidine-5'-(5-oxo-pentanoate)(ester), 2',3'-Dideoxy-5[[1-(2',3'-dideoxy-pentofuranosyl) -1,2-dihydro-2-oxo-4-pyrimidinyl]amino]-adenosine 5'-(5-oxopentanoate)(ester), The instant invention also comprises novel intermediates used in the synthesis of the compounds of Formula I. These novel intermediates are made by beginning with compounds represented by the letter designations A and C; which are reacted with appropriate reagents to introduce conventional hydroxyl or amine blocking groups (such as tertbutyldimethylchlorosilyl or dimethylaminomethylene). The compounds of Formula I are useful for either preventing a retroviral infection in a subject or treating a subject infected with a retrovirus by administering to the subject a virus inactivating effective amount of the Formula I compounds or their pharmaceutically acceptable salts. The compounds of Formula I are particularly useful for preventing an HIV infection in a subject, or treating a subject infected with the HIV virus by administering to the subject a virus inactivating effective amount of the Formula I compounds or their pharmaceutically acceptable salts. The compounds of Formula I may be administered by any suitable route including orally and intravenously. Generally a suitable dose of the compounds of Formula I will be in the range of 1-150 mg/kg/day administered over 2-6 subdoses per day. While it is possible for the Formula I compounds to be administered alone it is preferable to present it as a pharmaceutical formulation. The formulations of the invention comprise at least one compound of Formula I together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Formulations include those suitable for oral, and intraveneous administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of a Formula I compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The Formula I compound may also be presented as a bolus, electuary or paste. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the Formula I compound in a free-flowing form such as a powder or granules, optionally mixed with an appropriate binder, lubricant, inert diluent, preservative, distinegrant, surface-active, or dispersing agent. Molded tablets may be made by molded in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Formulations suitable for intraveneous administration include aqueous and non-aqueous isotonic, sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; an aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules or vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above recited, or an appropriate fraction thereof, of the compounds of Formula I. In accordance with the present invention, the compounds of the formula I are prepared by a process which comprises selectively protecting the 5'-OH or an amino group of a 2',3'-dideoxynucleoside of the formula AH or CH wherein A and C are as above to yield a compound of the formula A'H or C'H wherein A' and C' is 2',3'-dideoxynucleoside radical corresponding to A and C wherein either the 5' hydroxy group or an amino group is blocked with a conventional hydroxy or amino blocking group; reacting the compounds A'H and C'H with a bifunctional reagent derived from the linker group B and removing the hydroxy and/or amino blocking groups from the reaction product. The compounds of Formula I consist of hetero and homodimers. The first step in the synthesis of the heterodimers begins with selective protection of the 5'-OH or the amino group of the 2',3'-dideoxynucleoside radical with conventional amine or hydroxy blocking groups. The general methods of attaching the blocking groups are well known to one skilled in the art. Examples 1 and 13 of the instant specification illustrate one method of attaching known hydroxyl and amine blocking groups respectively. After attachment of the appropriate blocking groups, the bifunctional linker is attached to yield an intermediate with the linker group incorporated onto the unprotected NH₂ or 5′-OH group. A subsequent condensation of this intermediate with a second 2′,3′-dideoxynucleoside followed by deprotection then yields the heterodimer. Selective protection of the 5′-OH group can be conveniently achieved by reaction with reagents such as tertbutyldimethylsilyl chloride, triphenylmethyl chloride, benzylchloride or tetrahydropyran. The most convenient method for selective protection of the amino group is a reaction with dimethylformamide dimethylacetal to give the dimethylamino methylene derivative of the amine. The preferred bifunctional linker reagents are the cyclic dicarboxylic acid anhydrides, chlorosulfonylisocyanate, carboxyisothiocyanate, carboxyisocyanate, chlorosulfonylacetyl chloride, methyl phosphonyldichloride etc. The condensation of the COOH group with either an OH or an NH₂ group is usually carried out in the presence of reagents such as dicyclohexylcarbodiimide/1-hydroxy benzotriazole, 1,1′-carbonyldiimidazole/potassium tert-butoxide, 2-bromo-1-methylpyridinium iodide/triethylamine, or 1,1-oxalyldiimidazole. The same technology can be used to prepare the homodimers by using two identical 2′,3′-dideoxynucleoside radicals. On the other hand, the homodimers can be prepared by direct reaction of dideoxynucleoside radicals with a dicarboxylic acid dihalide or other commonly used derivatives such as bis[2-(succinimidoOxycarbonyloxy)ethyl] sulfone, bis(sulfosuccinimidyl)suberate, disuccinimidyl suberate, dithiobis(succinimidyl propionate) etc.. Figure I illustrates the anti-retroviral activity of the instant compounds against HIV. The black bars represent survival of target cells when virus is added. The open bars represent survival in the absence of virus (control). The drug dose is listed along the x-axis. The present invention will be further described in connection with the following Examples which are set forth for the purposes of illustration only. EXAMPLE 1 2′,3′-Dideoxy-5′O[(1,1-dimethylethyl)dimethylsilyl]cytidine To a solution of 2.1 g (10 mmol) of 2′,3′-dideoxycytidine in 20 ml of dimethylformamide was added 750 mg (11 mmol) of imidazole and 1.7 g (11 mmol) of tert.butyl-dimethylchlorosilane. After stirring at ambient temperature for 15 hours, the reaction solution was evaporated in vacuo . The residue was chromatographed (0-10% MeOH in CH₂Cl₂) to give 5.6 g (75%) of a white solid. NMR (CDCl₃): 0.1 (s, 6H, 2CH₃), 0.9 (2, 9H 3CH₃), 1.8 - 2.7 (m, 4H, H-2′s and H-3′s), 3.74 (dd, J=2.4 and 11.6 Hz, 1H, H-5′a), 4.09 (dd, J-2.0 and 11.6 Hz, 1H, H-5′b), 4.18 (dt, 1H, H-4′), 5.77 (d, J=8Hz, 1H, H-5), 6.09 (dd, J=2.4 and 6.8 Hz, 1H, H-1′), 8.24 (d, J=8 Hz, 1H, H-6). EXAMPLE 2 3′-Azido-3′-deoxy-beta-D-erythro-thymidine 5′-(hydrogenbutanedioate) To a stirred solution of 1.7 g (6 mmol) of 3′-azido-3′-deoxy-beta-D-erythro-thymidine in 20 ml of dimethylformamide was added 198 mg (7.8 mmol) of sodium hydride. After 0.5 hours at ambient temperature. 770 mg (7.7 mmol) of succinic anhydride was added. After another 2 hours, the mixture was applied on a column containing 20 ml of AG 50 (H+) resin and eluted with distilled water. The eluate containing the product was lyophilized to a gummy oil which was purified by silica gel column chromatography (10 -25% MeOH in CH₂Cl₂), to give 2.05 g (93%) of a white solid. NMR (CDCL₃ + DMSO-d₆): 1.89 (5, 3H, CH₃), 2.39 and 2.63 (m, 6H, CH₂′s and H-2′), 4.00 (m, 1H, H-3′ or H-4′, 4.30 (m, 2H, H-3′ or H-4′ and H-5a), 4.44 (m, 1H, H-5′) 6.15 (t, J=7.0 Hz, 1H, H-1′), 7.3 (s, 1H, H-6), 12.4 (bs, 1H, NH) 13.3 (bs, 1H, COOH). EXAMPLE 3 3′-Azido-3′-deoxy-4[[1-[2′,3′-dideoxy-5′-0[(1,1-dimethylethyl)dimethylsilyl]-pentofuranosyl]-1,2-dihydro-2-oxopyrimidinyl]amino]beta-D-erythro-thymidine 5′-(4-oxobutanoate)(ester) To a solution of 210 mg (0.57 mmol) of 3′-Azido-3′-deoxy-beta-D-erythro-thymidine 5′-(hydrogenbutandioate) (from Example 2) in 3 ml of pyridine were added 235 mg (1.14 mmol) of dicyclohexylcarbodiimide and 154 mg (1.14 mmol) of 1-hydroxybenzotriazole. After 2 hours, 186 mg (0.57 mmol) of 2′,3′-dideoxy-5′0-[(1,1-dimethylethyl)dimethylsilyl] cytidine (from Example 1) was added and the mixture stirred overnight (16 hours) at ambient temperature. Water (1.5 ml) was then added to the reaction and the precipitate was removed by filtration and the filtrate was evaporated to dryness in vacuo . The residue was extracted with 50 ml dichloromethane and washed successively with 2 x 25 ml = 50 ml of saturated aqueous sodium bicarbonate and 2 x 25 ml = 50 ml of saturated aqueous sodium chloride and dried over sodium sulfate. Removal of the dichloromethane afforded the crude product as a gummy oil which was purified by silica gel column chromatography (0-10% MeOH in CH₂Cl₂), to give 270 mg (70%) of a white solid. NMR (CDCl₃): 0.1 (S, 6H, 2 CH₃), 0.9 (S, 9H 3 CH₃), 1.8-2.9 (m. 13H, H-2′s, H-3′, 5-CH₃ and 2 CH₂), 3.5-4.5 (m, 7H, H-3′, H-4′s and H-5′s), 6.1 (m, 2H, H-1′s), 7.3 (m, 2H, H-5 and H-6), 8.58 (d, J=8Hz, 1-H, H-6), 9.04 and 9.8 (2 bs, 2H, 2NH). EXAMPLE 4 5-N[2′3′-Dideoxy-5′0[(1,1-dimethylethyl)dimethylsilyl] cytidinyl]-5-oxopentanoic acid To a solution of 980 mg (3 mmol) of 2′3′-dideoxy-5′-0 [(1,1-dimethylethyl)dimethylsilyl]cytidine (from Example 1) in 6 ml of dimethylformamide was added 420 mg (3.7 mmol) of glutaric anhydride. After stirring overnight (16 hours) at ambient temperature and for another 4 hours at 50°C, the solvent was removed in vacuo . The residue was chromatographed to give 870 mg (66%) of a white solid. NMR (DMSO-d₆): 0.1 (s, 6H, 2CH₃), 0.9 (s, 9H, 3CH₃), 1.6 - 2.5 (m, 10H, 3CH₂, H-2′s, and H-3′s), 3.72 (dd, J=2.4 and 11.6 Hz, 1H, H-5′a), 3.96 (dd, J=2.0 and 11.6 Hz, 1H, H-5′b), 4.1 (m, 1H, H-4′), 5.90 (dd, J=1.8 and 6.8 Hz, 1H, H-1′), 7.18 (d, J=8 Hz, 1H, H-5), 8.35 (d, 1H, H-6). EXAMPLE 5 N,N′-(1,5-Dioxo-1,5-pentanediyl)bis-[2′3′-dideoxy-5′-0[1,1-dimethylethyl)dimethylsilyl]cytidine] To a solution of 1.1 g (2.5 mmol) of 5-N-[2′3′-Dideoxy-5′0-[(1,1-dimethylethyl)dimethylsilyl]cytidinyl]-5-oxopentanoic acid (from Example 4) in 10 ml of dimethylformamide was added 1.14 g (5.5 mmol) of dicyclohexylcarbodiimide and 406 mg (3 mmol) of 1-hydroxybenzotriazole. After 0.5 hour at ambient temperature, 813 mg (2.5 mmol) 2′3′-dideoxy-5′-0 [(1,1-dimethylethyl)dimethylsilyl]cytidine (from Example 1) was added and the mixture stirred overnight (16 hours) at ambient temperature. By following the work-up procedure described in Example 3, 344 mg (18%) of white solid was isolated after silica gel chromatography (5-15% MeOH in CH₂Cl₂). NMR (CDCl₃): 0.16 (2s, 12H, 4CH₃), 0.96 (s, 18H, 6CH₃), 1.8 - 2.7 (m, 14H, 3CH₂, H-2′s and H-3′s), 3.72 (dd, J=2.4 and 11.6 Hz, 2H, H-5′a), 4.10 (dd, J=2.0 and 11.6 Hz, 2H, H-5′b), 4.20 (m, 2H, H-4′), 6.06 (dd, J=1.8 and 6.8 Hz, 2H, H-1′), 7.12 (d, J=8Hz, 2H, H-5), 8.52 (d, 2H, H-6). EXAMPLE 6 2′,3′-Dideoxy-5[[1-(2′,3′-dideoxy-5′-0[(1,1-dimethylethyl) dimethylsilyl]pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]cytidine 5′-(5-oxopentanoate)(ester) To a solution of 450 mg (1 mmol) of 5-N[2′3′-dideoxy-5′-0[(1,1-dimethylethyl)dimethylsilyl]cytidinyl]-5-oxopentanoic acid (from Example 4) in 5 ml of dimethylformamide was added 200 mg (1.2 mmol) carbonyldiimidazole. After stirring at ambient temperature for 1 hour, 122 mg (1 mmol) of 2′3′-dideoxycytidine, followed by 34 mg (0.3 mmol) of potassium tert-butoxide was added. The mixture was stirred overnight (16 hours) at ambient temperature. After removal of solvent in vacuo , the residue was chromatographed (5-20% MeOH in CH₂Cl₂) to give 92 mg (14%) of a white solid. NMR (CDCl₃) 0.1 (2s, 6H, 2 CH₃), 0.9 (s, 9H, 3 CH₃), 1.8-2.6 (m, 14H, H-2′s, H-3′s and 3 CH₂), 3.7-4.4 (m, 6H, H-4′s and H-5′s), 5.7 (d, J=8Hz, 1H, H-5), 6.0 (m, 2H, H-1′s), 7.3 (d, H=8Hz, 1H, H-5), 7.8 (d, J=8Hz, 1H, H-6), 8.6 (d, J=Hz, 1H, H-6).) EXAMPLE 7 2′3′-Dideoxy-5-[[1-[2′,3′-dideoxy-5′-0[1,1-dimethylethyl) dimethylsilyl]pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl] amino]adenosine 5′-(5-oxopentanoate)(ester) By following the procedure and conditions described in Example 6, 160 mg (0.68 mmol) of 2′, 3′-dideoxyadenosine and 23 mg (0.2 mmol) of potassium tert-butoxide added to a reaction of 3.01 mg (0.68 mmol) of 5-N-[2′3′-dideoxy-5′-O(1,1-dimethylethyl)dimethylsilyl)cytidinyl]5-oxopentanoic acid (from Example 4) and 136 mg (0.82 mmol) of carbonyldiimidazole in 3.4 ml of dimethylformamide, followed by stirring for 17 hours, gave 65 mg (14%) of a white solid after silica gel chromatography (0-10% MeOH in CH₂Cl₂). NMR (CDCl₃) 0.16 (2s, 6H, 2CH₃), 0.86 (S, 9H, 3CH₃), 1.8-2.7 (m14H, 3CH₂, H-2′s and H3′s), 3.7-4.7 (m, 6H, H-4′s, and H-5′s), 6.1 (dd, J=1.6 and 6.0 Hz 1H, H-1′), 6,33 (dd J=4.0 and 68 Hz, 1H, H-1′), 7.44 (d, J=8Hz, 1H, H-5), 8.2 and 8.36 (2s, 2H, and H-8), 8.63 (d, J=8Hz, 1H, H-6). EXAMPLE 8 3′-Azido-3′-deoxy-4[[1-(2′,3′-dideoxy-pentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]-beta-D-erythro-thymidine-5′(4-oxobutanoate)(ester) To a solution of 160 mg (0.24 mmol) of 3′-azido-3′-deoxy-4[[1[2′,3′-dideoxy-5′-0[(1,1-dimethylethyl)dimethylsilyl]-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidyl]amino]beta-D-erythro-thymidine-5′-(4-oxobutanoate) (ester) (from Example 3) in 2 ml of tetrahydrofuran was added 0.4 ml (0.4 mmol) of a 1M solution tetrabutylammonium fluoride in tetrahydrofuran. After stirring at ambient temperature for 2 hours, the solvent was removed in vacuo to afford a solid which was purified by preparative liquid chromatography (15% MeOH in CH₂Cl₂), to give 80 mg (61%) of the desired product as a white solid. NMR (DMSO-d₆): 1.79 (s, 3H, CH₃), 1.8 -2.8 (m, 1 OH, CH₂′s, H-2′s and H-3′s), 3.58 (dd, J=2.4 and 11.6 Hz, 1H, H-5′a), 3.76 (dd, J= and Hz, 1H, H-5′b), 3.98, 4.10, 4.28 and 4.46 (m, 5H total, H-3′s, H-4′s and H-5′s), 5.10 (t, J=6Hz, 1H, OH), 5.94 (dd, J=2.4 and 6.8 Hz, 1H, H-1′), 6.15 (t, J= 6.4 Hz, 1H, H-1′), 7.17 (d, J=8Hz, 1H, H-5), 7.50 (s, 1H, H-6), 8.50 (d, J=8Hz, 1H, H-6), 10.93 and 11.36 (2bs, 2H, NH′s). EXAMPLE 9 3′-Azido-3′-deoxy-4[[1-(2′,3′-dideoxy-pentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]-beta-D-erythro-thymidine-5′-(4-oxo-butanoate)(ester) A mixture of 346 mg (0.94 mmol) of 3′-Azido-3′-deoxy-beta-D-erythro-thymidine-5′-(hydrogenbutandioate) (from Example 2), 197 mg (0.94 mmol) of 2′,3′-dideoxycytidine, 488 mg (2.37 mmol) of dicyclohexylcarbodiimide, 315 mg (2.33 mmol) of 1-hydroxybenzotriazole in 4 ml of pyridine was stirred overnight (16 hours) at ambient temperature. The solvent was removed in vacuo . Purification using preparative liquid chromatography (5-15% MeOH in CH₂Cl₂) gave 166 mg (32%) of a white solid. EXAMPLE 10 N,N′-(1,5-dioxo-1,5-pentanediyl)bis(2′,3′-dideoxycytidine) By following the procedures and conditions described in Example 8, 1 ml (1 mmol) of a 1 M solution tetrabutylammonium fluoride in tetrahydrofuran added to 340 mg (0.5 mmol) of N, N′-(1,5-dioxo-1,5-pentanediyl)bis [2′,3′-dideoxy-5′-0[(1,1-dimethylethyl dimethylsilyl]cytidine] (from Example 5) in 2 ml of tetrahydrofuran, followed by stirring for 4 hours, gave 157 mg (66%) of a white solid after silica gel chromatography (10-20% MeOH in CH₂Cl₂). NMR (DMSO-d₆): 1.7 - 2.5 (m, 7H, CH₂ and H-2′s and H-3′s), 3.55 (dd, J=2.4 and 11.6 Hz, 1H, H-5′a), 3.75 (dd, J=2.0 and 11.6 Hz, 1H, H-5′b), 4.08 (m, 1H, H-4′), 5.1 (t, J=5.2 H Z , 1H, OH), 5.90 (dd, J=1.8 and 6.8 Hz, 1H, H-1′), 7.17 (d, J=8 Hz, 1H, H-5), 8.45 (d, J=8 Hz, 1H, H-6). EXAMPLE 11 2′,3′-Dideoxy-5-[[1-(2′,3′-dideoxypentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]cytidine-5′-(5-oxopentanoate)(ester) By following the procedures and conditions described in Example 8, 0.1 ml (0.1 mmol) of a 1 M solution tetrabutylammonium fluoride in tetrahydrofuran added to 92 mg of 2′,3′-dideoxy-5-[[1-[2′,3′-dideoxy-5′-0 [(1,1-dimethylethyl)dimethylsilyl]pentofuranosyl]1,2-dihydro-2-oxo-4-pyrimidinyl]amino]cytidine 5′-(5-oxopentanoate) (ester) (from Example 6) in 0.5 ml of tetrahydrofuran, followed by stirring for 3 hours, gave 28 mg (36%) of a white solid after reverse-phase silica gel high performance liquid chromatography (20% CH₃CN in H₂O). NMR (CDCl₃ + CD₃OD): 1.8-2.6 (m, 14H, 3CH₂, H-2′s and H-3′s), 3.7 (dd, J= 3.8 and 12 Hz, 1H, H-5′), 4.0 (dd, J=2 and 12 Hz, 1H, H-5) 4.1-4.5 (m, 4H, 2H-4′ and H-5′s), 5.77 (d, J=8 Hz, 1H, H-5), 5.92 (dd, J=2.4 and 6.8 Hz, 1H, H-1′), 6.0 (dd, J=1.8 and 6.8 Hz, 1H, H-1′), 7.33 (d, 1H, J=8Hz, H-5), 7.78 (d, J=8Hz, 1H, H-6), 8.52 (d, J=8 Hz, 1H, H-6). EXAMPLE 12 2′,3′-Dideoxy-5[[1-(2′,3′-dideoxypentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]adenosine 5′-(5-oxopentanoate)(ester) By following the procedures and conditions described in Example 8, 0.15 ml (0.15 mmol) of a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran added to 65 mg (0.099 mmol) of 2′,3′-dideoxy-5[[1-[2′,3′-dideoxy-5′-0-[(1,1-dimethylethyl)dimethylsilyl)pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]adenosine 5′-(5-oxopentanoate)(ester) (from Example 7) in 1 ml of tetrahydrofuran, followed by stirring for 1.5 hours, gave 20 mg (37%) of a white solid after silica gel chromatography (4-12% MeOH in CH₂Cl₂). NMR (CDCl₃ + CH₃OD) 1.95-2.7 (m, 14H, 3 CH₂, H-2′s and H-3′s), 3.7 - 4.7 (m, 6H, H-4′s and H-5′s), 6.2 (dd, J=1.8 and 6.8 Hz, 1H, H-1′), 6.30 (dd, J=4.0 and 6.8 Hz, 1H, H-1′), 7.35 (d, J=8Hz, 1H, H-5), 8.19 and 8.32 (2s, 2H, H-2 and H-8), 8.40 (d, J=8 Hz, 1H, H-6) EXAMPLE 13 2′,3′-Dideoxy-N-[(dimethylamino)methylene]cytidine To a solution of 1.05 g (5 mmol) of 2′,3′-dideoxycytidine in 5 ml of dimethylformamide was added 2 ml (15 mmol) of N,N-dimethylformamide dimethylacetal. After stirring at ambient temperature for 15 hours, the reaction solution was evaporated in vacuo to give 1.2 (93%) of a pale yellow solid. NMR (CDCl₃): 1.8-2.6 (m, 4H, H-2′s and H-3′s), 3.76 (dd, J=4 and 12 Hz, 1H, H-5′a), 4.02 (dd, J=3 and 12 Hz, 1H, H-5′b), 4.24 (m, 1H, H-4′), 6.07 (d, J=8 Hz, H-5), 6.12 (dd, J=4 and 7 Hz, 1H, H-1′), 7.98 (d, J=8 Hz, 1H, H-6), 8.84 (s, 1H,=CH). EXAMPLE 14 2′,3′-Dideoxycytidine 5′,5″-carbonate To a solution of 380 mg (1.4 mmol) of 2′,3′-dideoxy N-[(dimethylamino)methylene)cytidine (from Example 13) in 4 ml of dimethylformamide was added 146 mg (1.09 mmol) of carbonyldiimidazole, followed by 23 mg (0.2 mmol) of potassium tert-butoxide. The mixture was stirred for 2 hours at ambient temperature. After removal of solvent in vacuo , the residue was dissolved in 5 ml of methanol containing 40 mg (0.2 mmol) of p-toluenesulfonic acid monohydrate. The mixture was stirred for 7 hours at ambient temperature. After removal of solvent in vacuo , the residue was chromatographed (20% MeOH in CH₂l₂) to give 106 mg (34%) of a white solid. NMR (DMSO-d₆): 1.65-2.35 (m, 8H, H-2′s and H-3′s), 4.15-4.35 (m, 6H, H-4′s and H-5′s), 5.65 (d, J=8Hz, 2H, 2H-5), 6.00 (dd, J=3.2 and 6.8 Hz, 2H, 2H-1′), 7.1 (m, 4H, 2 NH₂), 7.6 (d, J=8Hz, 2H, 2H-6).

Claims: A compound of the formula A- B- C I wherein A and C are each independently dideoxynucleoside radicals and B is a linking group represented by the formula a) -C(X)-CH₂) n -C(X)- b) -C(X)- c) -C(X)-NH-S(O)(O)- d) -C(O)-CH₂-S(O)(O)- e) -P(O)CH₃- f) -C(O)O-(CH₂)₂-S(O)(O)-(CH₂)₂-OC(O)- g) -C(O)-(CH₂)₂-S-S-(CH₂)₂-C(O)- h) -C(O)-(CH₂)₂-C(O)O-(CH₂)₂-OC(O)-(CH₂)-C(O)- wherein X is O or S; n is 2-6; B is attached to A at either an amino or the 5' hydroxy group of A; and C is attached to B at either an amino or 5'-hydroxy group of C; and pharmaceutically acceptable salts thereof. A compound of claim 1 wherein A or C is a dideoxycytidine, dideoxyadenosine or 3'-azido-3'-deoxythymidine radical. 3'-Azido-3'-deoxy-4[[1-[2',3'-dideoxy-pentofuranosyl) -1,2-dihydro-2-oxo-pyrimidinyl]amino]-beta-D-erythrothymidine 5'-(4-oxo -butanoate)(ester), N,N'-(1,5-dioxo-1,5-pentanediyl)-bis(2',3'-dideoxycytidine), 2',3'-Dideoxy-5-[[1-(2',3'-dideoxy-pentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]amino]cytidine-5'-(5-oxo-pentanoate)(ester), 2',3'-Dideoxy-5[[1-(2',3'-dideoxy-pentofuranosyl) -1,2-dihydro-2-oxo-4-pyrimidinyl]amino]-adenosine 5'-(5-oxopentanoate)(ester), A compound of the formula A'-B-C' I wherein A' or C' are dideoxynucleotide radicals B is as defined in claim 1 and is attached to A' at an amino group of A' and C' is attached to B' at the 5' hydroxy group of C' and one or more of the remaining 5' hydroxy groups or amino groups of A' or C' which is not linked to B are blocked with conventional hydroxyl or amino blocking groups. A compound as in claim 4 wherein the hydroxyl blocking group is tertbutyldimethyl chlorosilyl. A compound as in claim 4 wherein th amine blocking groups is dimethylaminomethylene. Compounds as in any one of claims 1-3 for use as medicaments. Process for the preparation of a compound as claimed in any one of claim 1-3 which comprises selectively protecting the 5'-OH or an amino group of a 2',3'-dideoxy-nucleoside of the formula AH or CH wherein A and C are as in claim 1 to yield a compound of the formula A'H or C'H wherein A' and C' is 2',3'-dideoxynucleoside radical corresponding to A and C wherein either the 5' hydroxy group or an amino group is blocked with a conventional hydroxy or amino blocking groups reacting the compounds A'H and C'H with a bifunctional reagent derived from the linker group B and removing the hydroxy and/or amino blocking groups from the reaction product. Pharmaceutical preparations containing a compound as claimed in any one of claims 1-3, and a conventional pharmaceutical carrier material. The use of Compounds as claimed in any one of claims 1-3 in the manufacture of pharmaceutical preparation for the treatment of retroviral infections.

Inventors: BRODER SAMUEL, MITSUYA HIROAKI, TAM STEVE, WEIGELE MANFRED, BRODER, SAMUEL, MITSUYA, HIROAKI, TAM, STEVE, WEIGELE, MANFRED
Applicants: HOFFMANN LA ROCHE, US HEALTH, F. HOFFMANN-LA ROCHE AG, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Application year: 1988
Main classification: C07D405
IPC codes: C07H19, A61P31, A61K31, C07D473, C07D405